The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies.
 
Manish Sharma
Consulting or Advisory Role - Bayer; Ipsen
Travel, Accommodations, Expenses - Merck
 
Daniel V.T. Catenacci
Honoraria - Amgen; Foundation Medicine; Genentech/Roche; Genmab; Guardant Health; Lilly; NantWorks; OncoPlex Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Genentech/Roche; OncoPlex Diagnostics
Speakers' Bureau - Foundation Medicine; Guardant Health; Lilly; NantWorks
Research Funding - Genentech; OncoPlex Diagnostics
 
Theodore Karrison
No Relationships to Disclose
 
Anubha Ganjoo
No Relationships to Disclose
 
Kenisha Allen
No Relationships to Disclose
 
Grace K. Suh
No Relationships to Disclose
 
Brooke Elizabeth Phillips
No Relationships to Disclose
 
Robert de Wilton Marsh
No Relationships to Disclose
 
Mark Kozloff
No Relationships to Disclose
 
Blase N. Polite
Speakers' Bureau - Bayer/Onyx
Research Funding - Merck
Other Relationship - Gerson Lehrman Group
 
Hedy L. Kindler
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; MedImmune; Merck; Plexxikon; Verastem
Research Funding - AB Science; Aduro Biotech; Astellas Pharma; AstraZeneca; Bayer; Celgene; GlaxoSmithKline; Incyte; MedImmune; Merck; Verastem
Expert Testimony - Aduro Biotech